Beijing Beilu Pharmaceutical Company Limited operates in the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Beijing Beilu Pharmaceutical Company Limited with three other
companies in this sector in CHINA :
PharmaBlock Sciences Nanjing Inc
sales of 662.23 million Chinese Renmimbi [US$100.55 million]
of which 73%
was Above kg class),
Kingworld Medicines Group Limited
(977.93 million Chinese Renmimbi [US$148.49 million]
of which 91%
was Distribution sales of pharmaceutical and), and
GuangYuYuan Chinese Herbal Medicine Co Ltd
(1.21 billion Chinese Renmimbi [US$184.32 million]
of which 87%
was Drug Industry).
Beijing Beilu Pharmaceutical Company Limited reported sales of 819.12 million Chinese Renmimbi (US$124.38 million)
December of 2019.
increase of 34.7%
versus 2018, when the company's sales were 608.05 million Chinese Renmimbi.
Sales at Beijing Beilu Pharmaceutical Company Limited have increased during each of the previous five years
(and since 2014, sales have increased a total of 86%).
Sales of Pharmaceutical Sales saw an increase
35.3% in 2019, from
605.55 million Chinese Renmimbi to 819.11 million Chinese Renmimbi.
Not all segments of Beijing Beilu Pharmaceutical Company Limited experienced an increase in sales in 2019:
sales of Other Operation fell 99.5% to 11,320.75 Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).